| Year |
Citation |
Score |
| 2020 |
Cripe LD, Baker L, Sargent K, Martin C, Cottingham AH. Relationship described by bereaved caregivers (BCGs) between blood transfusions and hospice utilization for loved-ones (LOs) who died from acute myeloid leukemia (AML). Journal of Clinical Oncology. 38: e24002-e24002. DOI: 10.1200/Jco.2020.38.15_Suppl.E24002 |
0.322 |
|
| 2020 |
Cripe LD, Martin C, Sargent K, Baker L, Cottingham AH. Searching for the “exit ramp”: Bereaved caregivers (BCGs) describe discontinuation of transfusions at the end of life (EOL) for loved-ones (LOs) dying from acute myeloid leukemia (AML). Journal of Clinical Oncology. 38: e24000-e24000. DOI: 10.1200/Jco.2020.38.15_Suppl.E24000 |
0.33 |
|
| 2019 |
Ustun C, Le-Rademacher J, Wang HL, Othus M, Sun Z, Major B, Zhang MJ, Storrick E, Lafky JM, Chow S, Mrózek K, Attar EC, Nand S, Bloomfield CD, Cripe LD, et al. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. Leukemia. PMID 31073153 DOI: 10.1038/S41375-019-0477-X |
0.389 |
|
| 2019 |
Rangaraju S, Marino S, Roodman GD, Cripe LD, Ramdas B, Palam LR, Sargent KJ, Sayar H, Konig H, Kapur R, Boswell HS. Cooperativity between Flt3/Syk and Proteasome Inhibitors in Flt3mutant/Wildtype AML, By Acting on the Oxphos and Wnt Endpoints of Syk and p62SQSTM1 Pathways Prohibits Protective Autophagy; While Downregulation of NRF2, NQO1, Jun, and b-Catenin Bypasses Interfering RAS or WT1 Co-Mutations Blood. 134: 5051-5051. DOI: 10.1182/Blood-2019-124384 |
0.321 |
|
| 2018 |
Ignatz-Hoover JJ, Wang V, Mackowski NM, Roe AJ, Ghansah IK, Ueda M, Lazarus HM, de Lima M, Paietta E, Fernandez H, Cripe L, Tallman M, Wald DN. Aberrant GSK3β nuclear localization promotes AML growth and drug resistance. Blood Advances. 2: 2890-2903. PMID 30385433 DOI: 10.1182/Bloodadvances.2018016006 |
0.319 |
|
| 2018 |
Cripe LD, Rand KL, Perkins SM, Tong Y, Schmidt KK, Hedrick DG, Rawl SM. Ambulatory Advanced Cancer Patients' and Oncologists' Estimates of Life Expectancy Are Associated with Patient Psychological Characteristics But Not Chemotherapy Use. Journal of Palliative Medicine. PMID 29905496 DOI: 10.1089/Jpm.2017.0686 |
0.355 |
|
| 2018 |
Ganzel C, Sun Z, Cripe LD, Fernandez HF, Douer D, Rowe JM, Paietta EM, Ketterling R, O'Connell MJ, Wiernik PH, Bennett JM, Litzow MR, Luger SM, Lazarus HM, Tallman MS. Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience. American Journal of Hematology. PMID 29905379 DOI: 10.1002/Ajh.25162 |
0.371 |
|
| 2018 |
Fischer IC, Cripe LD, Rand KL. Predicting symptoms of anxiety and depression in patients living with advanced cancer: the differential roles of hope and optimism. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. PMID 29681016 DOI: 10.1007/S00520-018-4215-0 |
0.308 |
|
| 2018 |
Burns DS, Meadows AN, Althouse S, Perkins SM, Cripe LD. Differences between Supportive Music and Imagery and Music Listening during Outpatient Chemotherapy and Potential Moderators of Treatment Effects. Journal of Music Therapy. PMID 29471518 DOI: 10.1093/Jmt/Thy001 |
0.693 |
|
| 2018 |
Sayar H, Liu Y, Gao R, Zaid MA, Cripe LD, Weisenbach J, Sargent KJ, Nassiri M, Li L, Konig H, Suvannasankha A, Pan F, Shanmugam R, Goswami C, Kapur R, et al. Consecutive epigenetically-active agent combinations act inandpathways forAML. Oncotarget. 9: 5703-5715. PMID 29464028 DOI: 10.18632/Oncotarget.23655 |
0.356 |
|
| 2018 |
Ustun C, Le-Rademacher J, Wang H, Othus M, Sun Z, Major B, Zhang M, Storrick E, Lafky JM, Chow S, Mrózek K, Attar EC, Bloomfield CD, Cripe LD, Larson RA, et al. Allogeneic Hematopoietic Cell Transplantation (HCT) Vs. Non-HCT Consolidation Therapies in Acute Myeloid Leukemia (AML) Patients 60-75 Years of Age in First Complete Remission (CR1): An Alliance (A151509), SWOG, ECOG-ACRIN and CIBMTR Study Blood. 132: 2170-2170. DOI: 10.1182/Blood-2018-99-118383 |
0.349 |
|
| 2018 |
Rangaraju S, Marino S, Petrusca DN, Cripe LD, Sargent KJ, Roodman GD, Sayar H, Ramdas B, Palam LR, Shanmugam R, Rogozea A, Konig H, Kapur R, Boswell HS. Identification of Beta-Catenin As a Novel Ubiquitin-Regulated Target of Combined Flβ3/Syk- and Proteasome Inhibitors for Interruption of LSC Signaling in Poor-Risk AML Blood. 132: 3949-3949. DOI: 10.1182/Blood-2018-99-111181 |
0.315 |
|
| 2017 |
Cottingham AH, Cripe LD, Rand KL, Frankel RM. "My Future is Now": A Qualitative Study of Persons Living With Advanced Cancer. The American Journal of Hospice & Palliative Care. 1049909117734826. PMID 28992715 DOI: 10.1177/1049909117734826 |
0.328 |
|
| 2017 |
Strickland SA, Sun Z, Ketterling RP, Cherry AM, Cripe LD, Dewald G, Fernandez HF, Hicks GA, Higgins RR, Lazarus HM, Litzow MR, Luger SM, Paietta EM, Rowe JM, Vance GH, et al. Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials. Leukemia Research. 59: 55-64. PMID 28551161 DOI: 10.1016/J.Leukres.2017.05.010 |
0.363 |
|
| 2017 |
Saliba AN, Boswell HS, Cripe LD, Zaid MIA, Weisenbach J, Sayar H. Final Results of Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib in Acute Myeloid Leukemia with FLT3-ITD Mutation or Poor-Risk Cytogenetics Blood. 130: 3897-3897. DOI: 10.1182/Blood.V130.Suppl_1.3897.3897 |
0.413 |
|
| 2016 |
Ganzel C, Manola J, Douer D, Rowe JM, Fernandez HF, Paietta EM, Litzow MR, Lee JW, Luger SM, Lazarus HM, Cripe LD, Tallman MS. Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27573652 DOI: 10.1200/Jco.2016.67.5892 |
0.379 |
|
| 2016 |
Rand KL, Banno DA, Shea AM, Cripe LD. Life and treatment goals of patients with advanced, incurable cancer. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. PMID 26864986 DOI: 10.1007/S00520-016-3113-6 |
0.365 |
|
| 2015 |
Cripe LD, Hedrick DG, Rand KL, Burns D, Banno D, Cottingham A, Litzelman D, Hoffmann ML, Martenyi N, Frankel RM. Medical Students' Professionalism Narratives Reveal That Experiences With Death, Dying, or Palliative Care Are More Positive Than Other Experiences During Their Internal Medicine Clerkship. The American Journal of Hospice & Palliative Care. PMID 26430135 DOI: 10.1177/1049909115609296 |
0.648 |
|
| 2015 |
Cesano A, Willman CL, Kopecky KJ, Gayko U, Putta S, Louie B, Westfall M, Purvis N, Spellmeyer DC, Marimpietri C, Cohen AC, Hackett J, Shi J, Walker MG, Sun Z, ... ... Cripe LD, et al. Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemia. Plos One. 10: e0118485. PMID 25884949 DOI: 10.1371/Journal.Pone.0118485 |
0.345 |
|
| 2015 |
Burns DS, Perkins SM, Tong Y, Hilliard RE, Cripe LD. Music Therapy Is Associated With Family Perception of More Spiritual Support and Decreased Breathing Problems in Cancer Patients Receiving Hospice Care. Journal of Pain and Symptom Management. PMID 25839735 DOI: 10.1016/J.Jpainsymman.2015.02.022 |
0.665 |
|
| 2015 |
Sayar H, Czader M, Amin C, Cangany M, Konig H, Cripe LD. Pilot study of erlotinib in patients with acute myeloid leukemia. Leukemia Research. 39: 170-2. PMID 25498508 DOI: 10.1182/Blood.V122.21.5037.5037 |
0.429 |
|
| 2015 |
Stuart RK, Cripe LD, Maris MB, Cooper MA, Stone RM, Dakhil SR, Turturro F, Stock W, Mason J, Shami PJ, Strickland SA, Costa LJ, Borthakur G, Michelson GC, Fox JA, et al. REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia. British Journal of Haematology. 168: 796-805. PMID 25403830 DOI: 10.1111/Bjh.13214 |
0.336 |
|
| 2015 |
Lancet JE, Roboz GJ, Cripe LD, Michelson GC, Fox JA, Leavitt RD, Chen T, Hawtin R, Craig AR, Ravandi F, Maris MB, Stuart RK, Karp JE. A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia. Haematologica. 100: 231-7. PMID 25381131 DOI: 10.3324/Haematol.2014.114769 |
0.36 |
|
| 2015 |
Khawaja MR, Perkins SM, Schwartz JE, Robertson MJ, Kiel PJ, Sayar H, Cox EA, Vance GH, Farag SS, Cripe LD, Nelson RP. Cyclophosphamide/fludarabine nonmyeloablative allotransplant for acute myeloid leukemia. American Journal of Hematology. 90: 97-9. PMID 25345651 DOI: 10.1002/Ajh.23875 |
0.385 |
|
| 2015 |
Stage E, Czader M, O'Leary H, Boswell HS, Cripe LD, Sayar H, Dos Santos C, Levis MJ, Konig H. The Combination of the Novel Syk Inhibitor TAK659 with Decitabine Exerts Synergistic Cytotoxic Effects Against FLT3/ITD Mutated Acute Myeloid Leukemia Cells Blood. 126: 4928-4928. DOI: 10.1182/Blood.V126.23.4928.4928 |
0.316 |
|
| 2015 |
Ganzel C, Cripe LD, Sun Z, Fernandez HF, Cassileth PA, Douer D, Rowe JM, Paietta E, O'Connell M, Wiernik PH, Bennett JM, Litzow MR, Luger S, Lazarus HM, Tallman MS. Very Poor Long-Term Survival, Also in Contemporary Studies, of Patients with AML Who Relapse after Achieving a First Complete Remission: The ECOG-ACRIN Cancer Research Group Experience Blood. 126: 1315-1315. DOI: 10.1182/Blood.V126.23.1315.1315 |
0.368 |
|
| 2014 |
Khawaja MR, Cripe LD, Schwartz JE, Kiel P, Fausel CA, Sayar H, Robertson MJ, Abonour R, Cornetta K, Farag S, Nelson RP. Cyclophosphamide/fludarabine-based nonmyeloablative matched related/unrelated allotransplant for myelodysplasia. Journal of Clinical Oncology. 32: 7042-7042. DOI: 10.1200/Jco.2014.32.15_Suppl.7042 |
0.347 |
|
| 2014 |
Abu Zaid M, Boswell HS, Cripe LD, Liu Y, Weisenbach J, Sayar H. Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib in Acute Myeloid Leukemia with FLT3-ITD Mutation or Monosomy 5, 7, or Complex Cytogenetics Blood. 124: 976-976. DOI: 10.1182/Blood.V124.21.976.976 |
0.413 |
|
| 2013 |
Cesano A, Putta S, Rosen DB, Cohen AC, Gayko U, Mathi K, Woronicz J, Hawtin RE, Cripe L, Sun Z, Tallman MS, Paietta E. Functional pathway analysis using SCNP of FLT3 receptor pathway deregulation in AML provides prognostic information independent from mutational status. Plos One. 8: e56714. PMID 23431389 DOI: 10.1371/Journal.Pone.0056714 |
0.36 |
|
| 2013 |
Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg SL, Bhushan V, Shammo J, Hohl R, Verma A, Garcia-Manero G, Li YP, Lowe A, Zhu J, et al. Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome. Leukemia. 27: 977-80. PMID 23032694 DOI: 10.1038/Leu.2012.264 |
0.321 |
|
| 2013 |
Ganzel C, Manola J, Douer D, Rowe JM, Fernandez HF, Paietta E, Litzow MR, Lee J, Luger SM, Lazarus HM, Cripe L, Oken MM, Cassileth PA, Tallman MS. Extramedullary Disease Is Common In Newly Diagnosed AML But Has No Independent Prognostic Significance, Including CNS Involvement: Analysis Of 3,522 AML Patients Treated On Consecutive ECOG Trials 1980-2008 Blood. 122: 63-63. DOI: 10.1182/Blood.V122.21.63.63 |
0.364 |
|
| 2013 |
Boswell HS, Gupta S, Gao R, Sargent KJ, Cripe LD, Nassiri M, Sayar H, Liu Y. High-Risk AML, Including Flt3ITD+, Exhibits Resistance To Conventional Cytarabine Induction Associated With Diminished ENT1 and p16INK Expression: Evidence For Epigenetic Repression and HDAC Inhibitor Modulated De-Repression Blood. 122: 2525-2525. DOI: 10.1182/Blood.V122.21.2525.2525 |
0.413 |
|
| 2013 |
Barreyro L, Mitchell K, Will B, Bartholdy B, Zhou L, Todorova T, Stanley R, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling R, Cripe L, et al. Abstract C225: IL1RAP as functionally relevant target for stem-cell directed therapy in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C225 |
0.392 |
|
| 2012 |
Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling RP, Cripe L, Fernandez HF, et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood. 120: 1290-8. PMID 22723552 DOI: 10.1182/Blood-2012-01-404699 |
0.333 |
|
| 2012 |
Hardesty BM, Cripe LD. Cytarabine in relapsed acute myeloid leukemia. Leukemia Research. 36: 387-8. PMID 22285506 DOI: 10.1016/J.Leukres.2011.12.001 |
0.316 |
|
| 2012 |
Rand KL, Cripe LD, Monahan PO, Tong Y, Schmidt K, Rawl SM. Illness appraisal, religious coping, and psychological responses in men with advanced cancer. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 20: 1719-28. PMID 21927993 DOI: 10.1007/S00520-011-1265-Y |
0.302 |
|
| 2012 |
Cesano A, Willman CL, Kopecky KJ, Gayko U, Putta S, Louie B, Westfall M, Purvis N, Spellmeyer D, Marimpietri C, Hackett J, Shi J, Paietta E, Tallman MS, Cripe LD, et al. Single-Cell Network Profiling (SCNP)-Based Classifier to Predict Response to Induction Therapy in Elderly Patients with Acute Myeloid Leukemia (AML): Validation in Two Independent Sample Sets From ECOG and SWOG Trials. Blood. 120: 2489-2489. DOI: 10.1182/Blood.V120.21.2489.2489 |
0.34 |
|
| 2012 |
Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley R, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling RP, Cripe LD, Fernandez HF, et al. Parallel Transcriptional Analysis of Multiple Stem and Progenitor Populations Identifies Novel Commonly Dysregulated and Functionally Relevant Targets in AML Blood. 120: 1875-1875. DOI: 10.1182/Blood.V120.21.1875.1875 |
0.359 |
|
| 2011 |
Khawaja MR, Schwartz JE, Yu M, Robertson MJ, Vance GH, Srivastava S, Wood LL, Abonour R, Cornetta K, Farag S, Cripe LD, Nelson RP. Survival after nonmyeloablative versus myeloablative allotransplantation for AML/MDS. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 6563. PMID 28020177 DOI: 10.1200/Jco.2011.29.15_Suppl.6563 |
0.342 |
|
| 2011 |
Lancet JE, Ravandi F, Ricklis RM, Cripe LD, Kantarjian HM, Giles FJ, List AF, Chen T, Allen RS, Fox JA, Michelson GC, Karp JE. A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia. Leukemia. 25: 1808-14. PMID 21760592 DOI: 10.1038/Leu.2011.157 |
0.382 |
|
| 2011 |
Sayar H, Chan RJ, Orschell CM, Chan EM, Yu Z, Hood D, Plett A, Yang Z, Hui CL, Nabinger SC, Kohlbacher KJ, West ES, Walter A, Sampson C, Wu J, ... Cripe LD, et al. Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: a study of the Hoosier Oncology Group. Leukemia Research. 35: 1108-10. PMID 21420732 DOI: 10.1016/J.Leukres.2011.02.025 |
0.336 |
|
| 2011 |
Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni G, Godley LA, Langston AA, Amadori S, et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. Blood. 117: 3294-301. PMID 21270442 DOI: 10.1182/Blood-2010-08-301796 |
0.434 |
|
| 2011 |
Cesano A, Putta S, Mathi K, Rosen DB, Gayko U, Hawtin RE, Cripe LD, Sun Z, Tallman MS, Paietta E. Single Cell Network Profiling (SCNP) Functionally Characterizes FLT3 Pathway Deregulation in Non-M3 Acute Myeloid Leukemia (AML) and Provides Prognostic Value Independent From Mutational Status Blood. 118: 2512-2512. DOI: 10.1182/Blood.V118.21.2512.2512 |
0.345 |
|
| 2010 |
Cripe LD, Uno H, Paietta EM, Litzow MR, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Luger S, Tallman MS. Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood. 116: 4077-85. PMID 20716770 DOI: 10.1182/Blood-2010-04-277269 |
0.36 |
|
| 2010 |
Mesa RA, Yao X, Cripe LD, Li CY, Litzow M, Paietta E, Rowe JM, Tefferi A, Tallman MS. Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903. Blood. 116: 4436-8. PMID 20651074 DOI: 10.1182/Blood-2010-05-287417 |
0.332 |
|
| 2010 |
Nelson RP, Yu M, Schwartz JE, Robertson MJ, Hromas R, Fausel CA, Vance GH, Dlouhy SR, Baute JA, Cox EA, Wood LL, Srivastava S, Robertson KA, Haut PR, Farag SS, ... ... Cripe LD, et al. Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia. Bone Marrow Transplantation. 45: 1300-8. PMID 20062092 DOI: 10.1038/Bmt.2009.348 |
0.346 |
|
| 2010 |
Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 115: 2578-85. PMID 19965662 DOI: 10.1182/Blood-2009-08-236471 |
0.349 |
|
| 2010 |
Litzow MR, Othus M, Cripe LD, Gore SD, Lazarus HM, Lee SJ, Bennett JM, Paietta EM, Dewald GW, Rowe JM, Tallman MS. Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. British Journal of Haematology. 148: 217-25. PMID 19804455 DOI: 10.1111/J.1365-2141.2009.07917.X |
0.41 |
|
| 2010 |
Roboz GJ, Lancet JE, Cripe LD, Ravandi Kashani F, List AF, Fox JA, Michelson G, Karp JE. Final results of a phase II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia. Journal of Clinical Oncology. 28: 6526-6526. DOI: 10.1200/Jco.2010.28.15_Suppl.6526 |
0.339 |
|
| 2010 |
Stuart RK, Ravandi Kashani F, Cripe LD, Maris MB, Cooper MA, Dakhil SR, Stone RM, Turturro F, Fox JA, Michelson G. Voreloxin single-agent treatment of older patients (60 years or older) with previously untreated acute myeloid leukemia: Final results from a phase II study with three schedules. Journal of Clinical Oncology. 28: 6525-6525. DOI: 10.1200/Jco.2010.28.15_Suppl.6525 |
0.36 |
|
| 2010 |
Strickland SA, Sun Z, Ketterling RP, Cherry AM, Cripe LD, Dewald G, Higgins RR, Lazarus HM, Litzow MR, Luger SM, Paietta E, Rowe JM, Uno H, Vance GH, Tallman MS. Monosomal Karyotype (MK) In Older Patients with Acute Myeloid Leukemia (AML) on Eastern Cooperative Oncology Group (ECOG) Therapeutic Trials: Poor Prognostic Impact of MK, but Not of Monosomy 7 Blood. 116: 579-579. DOI: 10.1182/Blood.V116.21.579.579 |
0.378 |
|
| 2010 |
Sayar H, Cripe L, Cangany M, Weisenbach J, Sargent KJ, Goswami C, Li L, Wilson-Weekes A, Shanmugam R, Boswell HS. Cyclic Administration of Combination of Sorafenib and Vorinostat In Poor-Risk AML: A Pharmacodynamically-Oriented Extended Phase I Trial Blood. 116: 3272-3272. DOI: 10.1182/Blood.V116.21.3272.3272 |
0.418 |
|
| 2010 |
Rosen DB, Putta S, Gayko U, Cesano A, Cripe L, Sun Z, Litzow MR, Uno H, Tallman MS, Paietta E. Characterization of FLT3 Pathway Deregulation by Single Cell Network Profiling (SCNP) Stratifies AML Patients Beyond Molecular Profiling Blood. 116: 2739-2739. DOI: 10.1182/Blood.V116.21.2739.2739 |
0.339 |
|
| 2010 |
Cesano A, Putta S, Gayko U, Hackett J, Rosen DB, Cripe L, Sun Z, Uno H, Litzow MR, Tallman MS, Paietta E. Single-Cell Network Profiliing (SCNP) Signatures Independently Predict Response to Induction Therapy In Older Patients with Acute Myeloid Leukemia (AML) Blood. 116: 2695-2695. DOI: 10.1182/Blood.V116.21.2695.2695 |
0.366 |
|
| 2010 |
Cesano A, Rosen DB, Putta S, Gayko U, Cripe L, Sun Z, Uno H, Litzow MR, Tallman MS, Paietta E. Specimen Source (BM or PB) Does Not Affect Proteomic Signaling In Patients with AML and Circulating Blasts Blood. 116: 2693-2693. DOI: 10.1182/Blood.V116.21.2693.2693 |
0.355 |
|
| 2010 |
Baghdadi TA, Goswami C, Sayar H, Sargent KJ, Cripe L, Li L, Shanmugam R, Boswell HS. A Pathway-focused GSEA Platform In AML That Interrogates Interaction of Flt3ITD and tMLL with Their Epigenetic Targets (p16INK4a, DAPK1, and RUNX3), While Accurately Reporting Broad-based AML Prognosis and Targeting-agent Sensitivity. Blood. 116: 1660-1660. DOI: 10.1182/Blood.V116.21.1660.1660 |
0.339 |
|
| 2009 |
Maris MB, Ravandi F, Stuart R, Stone R, Cripe L, Cooper M, Strickland S, Turturro F, Stock W, Berman C. A phase II study of voreloxin as single agent therapy for elderly patients (pts) with newly diagnosed acute myeloid leukemia (AML). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 7048. PMID 27961427 DOI: 10.1200/Jco.2009.27.15_Suppl.7048 |
0.311 |
|
| 2009 |
Lancet JE, Karp J, Cripe L, Roboz G, Wollman M, Berman C, Conroy A, Hawtin R, Fox J, Michelson G. Phase Ib/II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in relapsed or refractory AML patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 7005. PMID 27961377 DOI: 10.1200/Jco.2009.27.15_Suppl.7005 |
0.32 |
|
| 2009 |
Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni G, Godley LA, Langston AA, Amadori S, et al. Results From a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for FLT3 Mutant AML Patients in First Relapse. Blood. 114: 788-788. DOI: 10.1182/Blood.V114.22.788.788 |
0.423 |
|
| 2009 |
Lancet JE, Roboz GJ, Cripe LD, Maris M, List AF, Fox J, Michelson GC, Karp J. Phase 1b/2 Pharmacokinetic/Pharmacodynamic (PK/PD) Study of Combination Voreloxin and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia Patients. Blood. 114: 635-635. DOI: 10.1182/Blood.V114.22.635.635 |
0.314 |
|
| 2009 |
Shanmugam R, Wilson-Weekes A, Sayar H, Suvannasankha A, Cardoso AA, Sargent KJ, Cripe LD, Kalvakolanu DV, Boswell HS. Transcriptional Repression of DAPK1 Characterizes a Resistant Phenotype of AML Enforced by Flt3 Signaling and Exclusive Nuclear Abundance of Non-Canonical NFkB2/p52: Synergistic Activity for Flt3 Inhibition along with HDAC Inhibition, or by NFkB Inhibition, for Potentiating ER Stress Apoptosis. Blood. 114: 2387-2387. DOI: 10.1182/Blood.V114.22.2387.2387 |
0.34 |
|
| 2009 |
Farag S, Wood LL, Schwartz JE, Srivastava S, Nelson RP, Robertson M, Abonour R, Sayar H, Cripe LD. Phase I Trial of High-Dose Clofarabine and Busulfan as a Myeloablative Regimen Prior to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia. Blood. 114: 198-198. DOI: 10.1182/Blood.V114.22.198.198 |
0.363 |
|
| 2009 |
Ravandi F, Kantarjian HM, Cripe LD, Maris M, Cooper M, Dakhil SR, Stone RM, Turturro F, Chen T, Mahadocon K, Fox J, Berman C, Michelson GC, Stuart RK. A Phase 2 Dose Regimen Optimization Study of Three Schedules of Voreloxin as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia. Blood. 114: 1037-1037. DOI: 10.1182/Blood.V114.22.1037.1037 |
0.336 |
|
| 2008 |
Giagounidis A, Fenaux P, Mufti GJ, Muus P, Platzbecker U, Sanz G, Cripe L, Von Lilienfeld-Toal M, Wells RA. Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes. Annals of Hematology. 87: 345-52. PMID 18265982 DOI: 10.1007/S00277-008-0449-0 |
0.338 |
|
| 2008 |
Burns DS, Azzouz F, Sledge R, Rutledge C, Hincher K, Monahan PO, Cripe LD. Music imagery for adults with acute leukemia in protective environments: a feasibility study. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 16: 507-13. PMID 17891547 DOI: 10.1007/S00520-007-0330-Z |
0.702 |
|
| 2008 |
Friedberg JW, Sharman J, Schaefer-Cutillo J, Johnston PB, De Vos S, LaCasce A, Leonard JP, Cripe LD, Sinha R, Gregory SA, Sweetenham J, Vose JM, Lowe AM, Levy R, Shipp MA. Fostamatinib Disodium (FosD), An Oral Inhibitor of Syk, Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B Cell Lymphoma (DLBCL) and Chronic Lymphocytic Leukemia (SLL/CLL) Blood. 112: 3-3. DOI: 10.1182/Blood.V112.11.3.3 |
0.356 |
|
| 2008 |
Wendtner CM, Mahadevan D, Stilgenbauer S, Frankfurt O, Bloor A, Bosch F, Uharek L, Furman RR, Gobbi M, Gribben JG, Kimby EK, Sekeres MA, Cripe LD, Lombardy E, Shah S, et al. Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL- 001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia. Blood. 112: 2104-2104. DOI: 10.1182/Blood.V112.11.2104.2104 |
0.372 |
|
| 2008 |
Maris M, Cripe LD, Stuart RK, Ravandi F, Michelson GC, Hawtin RE, Ericson LE, Berman CJ. Phase 2 Study of Voreloxin (Formerly Known as SNS-595) as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AML): Preliminary Safety and Clinical Responses (The REVEAL-1 Study). Blood. 112: 1951-1951. DOI: 10.1182/Blood.V112.11.1951.1951 |
0.423 |
|
| 2008 |
Mesa RA, Yao X, Cripe LD, Li CY, Tefferi A, Tallman MS. Lenalidomide and Prednisone for Primary and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis (MF): An Eastern Cooperative Oncology Group (ECOG) Phase II Trial. Blood. 112: 1753-1753. DOI: 10.1182/Blood.V112.11.1753.1753 |
0.401 |
|
| 2007 |
Fenaux P, Raza A, Mufti GJ, Aul C, Germing U, Kantarjian H, Cripe L, Kerstens R, De Porre P, Kurzrock R. A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood. 109: 4158-63. PMID 17264294 DOI: 10.1182/Blood-2006-07-035725 |
0.393 |
|
| 2007 |
Suvannasankha A, Fausel C, Juliar BE, Yiannoutsos CT, Fisher WB, Ansari RH, Wood LL, Smith GG, Cripe LD, Abonour R. Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21. The Oncologist. 12: 99-106. PMID 17227904 DOI: 10.1634/Theoncologist.12-1-99 |
0.408 |
|
| 2007 |
Hartman AD, Wilson-Weekes A, Ruffin T, Hincher KJ, Cripe LD, Boswell HS. Mechanistic Paradigm for Combination Signal Transduction Inhibitor Therapy in Zap70+ CLL Involves Bicompartmental Functions of EZH2. Blood. 110: 3099-3099. DOI: 10.1182/Blood.V110.11.3099.3099 |
0.3 |
|
| 2007 |
Lancet JE, Gotlib J, Wetzler M, Luger S, Cripe LD, Tallman MS, Gojo I, Mulford D, Baer MR, List AF, Multani PS, Sikic BI. Phase I/II Study of the P-Glycoprotein (Pgp) Inhibitor Zosuquidar Administered by Continuous Infusion (CIV) with Daunorubicin (DNR) and Cytarabine (ARA-C) as Primary Therapy in Older Patients with Pgp-Positive Acute Myeloid Leukemia (AML). Blood. 110: 299-299. DOI: 10.1182/Blood.V110.11.299.299 |
0.422 |
|
| 2006 |
Hartman AD, Wilson-Weekes A, Suvannasankha A, Burgess GS, Phillips CA, Hincher KJ, Cripe LD, Boswell HS. Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation. Experimental Hematology. 34: 1360-76. PMID 16982329 DOI: 10.1016/J.Exphem.2006.05.019 |
0.323 |
|
| 2006 |
Nelson RP, Cornetta K, Ward KE, Ramanuja S, Fausel C, Cripe LD. Desensitization to imatinib in patients with leukemia. Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology. 97: 216-22. PMID 16937754 DOI: 10.1016/S1081-1206(10)60016-6 |
0.325 |
|
| 2006 |
Cripe LD, Rader K, Tallman MS, Gordon MS, Paietta E, Bennett J, Neuberg D, Litzow MR, O'Brien TE, Rowe JM. Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997 Leukemia Research. 30: 823-827. PMID 16413056 DOI: 10.1016/J.Leukres.2005.11.006 |
0.371 |
|
| 2006 |
Hartman AD, Wilson-Weekes A, Cripe LD, Bennett B, Friedman G, Worland P, Druker B, Ren S, Skorski T, Boswell HS. In Chronic Lymphocytic Leukemia, Zap70 Identifies a Survival Pathway Signal Cascade Involving p85 PI-3-Kinase, CrkL, and Cbl with Syk En Route to JNK1 and bcl-2. Blood. 108: 584-584. DOI: 10.1182/Blood.V108.11.584.584 |
0.32 |
|
| 2006 |
Czader M, Wang M, Cripe LD, Cheng L, Orazi A. Loss of Heterozygosity in Bone Marrows of Patients with Iron-Deficiency Anemia. Blood. 108: 4863-4863. DOI: 10.1182/Blood.V108.11.4863.4863 |
0.303 |
|
| 2006 |
Lancet J, Baer MR, Cripe LD, List AF, Marcelletti JF, Multani PS, Sikic BI. Phase I/II Pharmacodynamic Study of the P-Glycoprotein (Pgp) Inhibitor Zosuquidar Administered by Continuous Infusion (CIV) with Daunorubicin (DNR) and Cytarabine (ARA-C) as Primary Therapy in Older Patients with Acute Myeloid Leukemia (AML). Blood. 108: 422-422. DOI: 10.1182/Blood.V108.11.422.422 |
0.369 |
|
| 2006 |
Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg S, Bhushan V, Shammo J, Hohl R, Li Y, Lowe A, Zhu J, List A. Phase I/II, Randomized, MultiCenter, Dose-Ascension Study of the p38MAPK Inhibitor Scio-469 in Patients with Myelodysplastic Syndrome (MDS). Blood. 108: 2657-2657. DOI: 10.1182/Blood.V108.11.2657.2657 |
0.343 |
|
| 2005 |
Suvannasankha A, Fausel C, Juliar BE, Yiannoutsos C, Wood LL, Smith GG, Cripe LD, Abonour R. Final report of a phase II study of oral cyclophosphamide, thalidomide, and prednisone (CTP) for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial: HEM01-21. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 6591. PMID 27943739 DOI: 10.1200/Jco.2005.23.16_Suppl.6591 |
0.361 |
|
| 2005 |
Kristeller JL, Rhodes M, Cripe LD, Sheets V. Oncologist Assisted Spiritual Intervention Study (OASIS): patient acceptability and initial evidence of effects. International Journal of Psychiatry in Medicine. 35: 329-47. PMID 16673834 DOI: 10.2190/8Ae4-F01C-60M0-85C8 |
0.311 |
|
| 2005 |
Ganjoo KN, Robertson MJ, Fisher W, Jung SH, McClean J, Huh SY, Bufill J, Williams S, Cripe LD. A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: a Hoosier Oncology Group Study. American Journal of Clinical Oncology. 28: 169-72. PMID 15803012 DOI: 10.1097/01.Coc.0000144812.74663.D0 |
0.379 |
|
| 2005 |
Rowe JM, Li X, Cassileth PA, Appelbaum FR, Schiffer CA, Wiernik PH, Litzow MR, Cripe LD, Lazarus HM, Paietta E, Dewald GW, Weinstein HJ, Ogden AK, Woods WG, Shepherd L, et al. Very Poor Survival of Patients with AML Who Relapse after Achieving a First Complete Remission: The Eastern Cooperative Oncology Group Experience. Blood. 106: 546-546. DOI: 10.1182/Blood.V106.11.546.546 |
0.386 |
|
| 2005 |
Levis M, Smith BD, Beran M, Baer MR, Erba HP, Cripe L, Coutre S, Advani A, Perl A, Devetten M, Stuart R, Tallman MS, Brown P, Tremmel L, Small D. A Randomized, Open-Label Study of Lestaurtinib (CEP-701), an Oral FLT3 Inhibitor, Administered in Sequence with Chemotherapy in Patients with Relapsed AML Harboring FLT3 Activating Mutations: Clinical Response Correlates with Successful FLT3 Inhibition. Blood. 106: 403-403. DOI: 10.1182/Blood.V106.11.403.403 |
0.425 |
|
| 2005 |
Burns DS, Azzouz F, Hincher K, Rutledge C, Monahan P, Cripe LD. A Music Imagery Intervention for Adults with Acute Leukemia in Protective Environments. Blood. 106: 3130-3130. DOI: 10.1182/Blood.V106.11.3130.3130 |
0.705 |
|
| 2005 |
Hartman AD, Wilson-Weekes A, Suvannasankha A, Burgess GS, Hincher KJ, Cripe LD, Boswell HS. In AML, Cbl Serves as Nexus for Signaling from Flt3, and Is Required for Coupling JNK1 in a Pathway of Survival and Proliferation Involving c-jun/AP-1. Blood. 106: 1203-1203. DOI: 10.1182/Blood.V106.11.1203.1203 |
0.324 |
|
| 2004 |
Vaena DA, Walker P, Pennington K, Stephens A, Stender MJ, Yiannoutsos CT, Young C, Stoner C, Cripe LD. Phase II study of low-dose topotecan in myelodysplastic syndromes: a Hoosier Oncology Group (HOG) study. Leukemia Research. 28: 49-52. PMID 14630080 DOI: 10.1016/S0145-2126(03)00181-4 |
0.371 |
|
| 2003 |
Fisch M, Zichi Cohen M, Rutledge C, Cripe LD. Teaching patients how to improve communication with their health care providers: a unique workshop experience. Journal of Cancer Education : the Official Journal of the American Association For Cancer Education. 18: 188-93. PMID 14766328 DOI: 10.1207/S15430154Jce1804_5 |
0.303 |
|
| 2003 |
Paietta E, Neuberg D, Bennett JM, Dewald G, Rowe JM, Cassileth PA, Cripe L, Tallman MS, Wiernik PH. Low expression of the myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trials. Leukemia. 17: 1544-50. PMID 12886241 DOI: 10.1038/Sj.Leu.2402999 |
0.322 |
|
| 2002 |
Cripe LD, Hinton S. Acute myeloid leukemia in adults. Current Treatment Options in Oncology. 1: 9-17. PMID 12057057 DOI: 10.1007/S11864-000-0011-3 |
0.393 |
|
| 2002 |
Douglas VK, Tallman MS, Cripe LD, Peterson LC. Thrombopoietin administered during induction chemotherapy to patients with acute myeloid leukemia induces transient morphologic changes that may resemble chronic myeloproliferative disorders. American Journal of Clinical Pathology. 117: 844-50. PMID 12047134 DOI: 10.1309/09Np-3Dfg-Blm9-E5Le |
0.344 |
|
| 2001 |
Porcu P, Cripe LD, Ng EW, Bhatia S, Danielson CM, Orazi A, McCarthy LJ. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leukemia & Lymphoma. 39: 1-18. PMID 10975379 DOI: 10.3109/10428190009053534 |
0.306 |
|
| 2000 |
Gordon MS, Young ML, Tallman MS, Cripe LD, Bennett JM, Paietta E, Longo W, Gerad H, Mazza J, Rowe JM. Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995. Leukemia Research. 24: 871-5. PMID 10996206 DOI: 10.1016/S0145-2126(00)00043-6 |
0.417 |
|
| 2000 |
Hromas R, Cripe L, Hangoc G, Cooper S, Broxmeyer HE. The Exodus subfamily of CC chemokines inhibits the proliferation of chronic myelogenous leukemia progenitors Blood. 95: 1506-1508. DOI: 10.1182/Blood.V95.4.1506.004K41_1506_1508 |
0.301 |
|
| 1997 |
Cripe LD. Adult acute leukemia. Current Problems in Cancer. 21: 1-64. PMID 9058027 DOI: 10.1016/S0147-0272(97)80006-2 |
0.433 |
|
| 1994 |
Reuther GW, Fu H, Cripe LD, Collier RJ, Pendergast AM. Association of the protein kinases c-Bcr and Bcr-Abl with proteins of the 14-3-3 family. Science (New York, N.Y.). 266: 129-33. PMID 7939633 DOI: 10.1126/Science.7939633 |
0.677 |
|
| 1993 |
Pendergast AM, Quilliam LA, Cripe LD, Bassing CH, Dai Z, Li N, Batzer A, Rabun KM, Der CJ, Schlessinger J. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein. Cell. 75: 175-85. PMID 8402896 |
0.533 |
|
| Show low-probability matches. |